Search

Your search keyword '"Limburg, P."' showing total 1,242 results
Start Over Author "Limburg, P."
1,242 results on '"Limburg, P."'

205. Allgemeines

Author

Brachetti, A. K. J., Emmrich, J., Limburg, H., Albrecht, M., Trams, G., Lehmann, F., Schulz, K. -D., Schmidt-Rhode, P., Weymar, P., Geiger, W., Künzig, H. J., Schleich, A., Wiest, W., Grumbrecht, C., Stosiek, U., Nord, D., Bastert, G., Michel, R. T., Fortmeyer, H. P., Schmidt-Matthiesen, H., Teufel, G., Ritter, R., Pfleiderer, A., Bastert, G., Schmidt-Matthiesen, G., Theobald, P., Pfau, P., Rahlf, G., Keller, E., Schmelzle, R., Maier, W., Schindler, A. E., Schrage, R., Schmid, H., Ulbrich, R., Rath, W., Limburg, H., Brachetti, A. K. J., Riede, U. N., Weymar, P., Schulz, K. D., Noldus, B., Schmidt-Rhode, P., Kaltenbach, F. J., Fettig, O., Kapp-Schwoerer, H., Ladner, H. -A., Hillemanns, H. -G., v. Fournier, D., Kubli, F., Bauer, M., Schneider-Affeld, F., Kaufmann, M., Sander, H., Wigand, K., Schulze, S., Keçecicoğlu, Y., Abts, H., Semm, K., Drähne, A., Kaufmann, I., and Kunz, S.

Published
1979
Full Text
View/download PDF

206. Rapid assessment of avoidable blindness-based healthcare costs of diabetic retinopathy in Hungary and its projection for the year 2045

Author

Tóth, Gábor, Limburg, Hans, Szabó, Dorottya, Sándor, Gábor L, Nagy, Zoltán Z, and Németh, János

Abstract

Background/aimsThe purpose of this study was to estimate the total healthcare cost associated with diabetic retinopathy (DR) in the population aged 18 years and older in Hungary, and its projection for the year 2045.MethodsA cost model was developed based on the standardised rapid assessment of avoidable blindness with the diabetic retinopathy module (RAAB+DRM) methodology and recently reported prevalent-based cost of illness model. Projection for 2045 was made based on the estimation for increasing diabetes mellitus (DM) prevalence of the International Diabetes Federation. Costs were analysed from the perspective of the healthcare system and the patients. Our DR cost model was constructed according to the Scottish DR grading scale and based on the DR severity stadium.ResultsThe total DR-associated healthcare cost was US$145.8 million in 2016 and will increase to US$169.0 million by 2045. The two major cost drivers were intravitreal antivascular endothelial growth factor injections and vitrectomies in this study (US$126.4 million in 2016 and US$146.5 million in 2045); they amounted to 86.7% of the total treatment cost of DR. The DR-related cost per patient was US$180.5 in Hungary.ConclusionsThe cost per patient for treating DR was lower in Hungary than in other countries. Due to the increasing socioeconomic burden of proliferative DR and diabetes-related blindness, it would be important to invest in DR screening, prevention and early treatment. Our new RAAB-based cost of DR model may facilitate comparisons of DR treatment costs across countries.

Published
2021
Full Text
View/download PDF

207. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population

Author

Fisher, Deborah A., Karlitz, Jordan J., Jeyakumar, Sushanth, Smith, Nathaniel, Limburg, Paul, Lieberman, David, and Fendrick, A. Mark

Abstract

AbstractAimMultiple screening strategies are guideline-endorsed for average-risk colorectal cancer (CRC). The impact of real-world adherence rates on the cost-effectiveness of non-invasive stool-based CRC screening strategies remains undefined.MethodsThis cost-effectiveness analysis from the perspective of Medicare as a primary payer used the Colorectal Cancer and Adenoma Incidence and Mortality Microsimulation Model (CRC–AIM) to estimate cost and clinical outcomes for triennial multi-target stool DNA (mt-sDNA), annual fecal immunochemical test (FIT) and annual fecal occult blood test (FOBT) screening strategies in a simulated cohort of US adults aged 65 years, who were assumed to either be previously unscreened or initiating screening upon entry to Medicare. Reported real-world adherence rates for initial stool-based screening and colonoscopy follow up (after a positive stool test result) were defined as 71.1% and 73.0% for mt-sDNA, 42.6% and 47.0% for FIT, and 33.4% and 47.0% for FOBT, respectively. The incremental cost-effectiveness ratio using quality-adjusted life years (QALY) was defined as the primary outcome of interest; other cost and clinical outcomes were also reported in secondary analyses. Multiple sensitivity and scenario analyses were conducted.ResultsWhen reported real-world adherence rates were included only for initial stool-based screening, mt-sDNA was cost-effective versus FIT ($62,814/QALY) and FOBT ($39,171/QALY); mt-sDNA also yielded improved clinical outcomes. When reported real-world adherence rates were included for both initial stool-based screening and follow-up colonoscopy (when indicated), mt-sDNA was increasingly cost-effective compared to FIT and FOBT ($31,725/QALY and $28,465/QALY, respectively), with further improved clinical outcomes.LimitationsResults are based on real-world cross-sectional adherence rates and may vary in the context of other types of settings. Only guideline-recommended stool-based strategies were considered in this analysis.ConclusionComparisons of the effectiveness and benefits of specific CRC screening strategies should include both test-specific performance characteristics and real-world adherence to screening tests and, when indicated, follow-up colonoscopy.

Published
2021
Full Text
View/download PDF

208. Long-lived charged states of single porphyrin-tape junctions under ambient conditionsElectronic supplementary information (ESI) available: Full details of the methods used can be found in the ESI Section 1 labelled Break junction experiments. The methodology used in the theoretical treatment can be found in ESI Section 2. See DOI: 10.1039/d0nh00415d

Author

Leary, Edmund, Kastlunger, Georg, Limburg, Bart, Rincón-García, Laura, Hurtado-Gallego, Juan, González, M. Teresa, Bollinger, Gabino Rubio, Agrait, Nicolás, Higgins, Simon J., Anderson, Harry L., Stadler, Robert, and Nichols, Richard J.

Abstract

The ability to control the charge state of individual molecules wired in two-terminal single-molecule junctions is a key challenge in molecular electronics, particularly in relation to the development of molecular memory and other computational componentry. Here we demonstrate that single porphyrin molecular junctions can be reversibly charged and discharged at elevated biases under ambient conditions due to the presence of a localised molecular eigenstate close to the Fermi edge of the electrodes. In particular, we can observe long-lived charge-states with lifetimes upwards of 1–10 seconds after returning to low bias and large changes in conductance, in excess of 100-fold at low bias. Our theoretical analysis finds charge-state lifetimes within the same time range as the experiments. The ambient operation demonstrates that special conditions such as low temperatures or ultra-high vacuum are not essential to observe hysteresis and stable charged molecular junctions.

Published
2021
Full Text
View/download PDF

209. Multitarget Stool DNA for Average Risk Colorectal Cancer Screening

Author

Kisiel, John B., Eckmann, Jason D., and Limburg, Paul J.

Abstract

After 2 screen-setting studies showing high sensitivity for colorectal cancer and advanced precancerous lesions, multitarget stool DNA testing was endorsed by the US Preventative Services Task Force as a first-line colorectal cancer screening test. Uptake has increased exponentially since approval by the US Food and Drug Administration and Centers for Medicare and Medicaid Services. Adherence to testing is approximately 70%. Patients with positive results have high diagnostic colonoscopy completion rates in single-center studies. The positive predictive value for colorectal neoplasia in postapproval studies is high. Next-generation test prototypes show promise to extend specificity gains while maintaining high sensitivity.

Published
2020
Full Text
View/download PDF

210. Effect of an Al(III) Complex on the Regio- and Stereoisomeric Formation of Bicyclic Organic Carbonates

Author

Maquilón, Cristina, Limburg, Bart, Laserna, Victor, Garay-Ruiz, Diego, González-Fabra, Joan, Bo, Carles, Martínez Belmonte, Marta, Escudero-Adán, Eduardo C., and Kleij, Arjan W.

Abstract

Valorization of carbon dioxide into organic molecules using catalytic approaches has witnessed an upsurge in recent years. Here, the influence of an Al(III) aminotriphenolate complex on the regio- and stereochemical features of the coupling between carbon dioxide and a cyclic epoxy alcohol has been studied. Three distinct bicyclic carbonate products were produced from a single starting material, depending on the catalytic conditions. The proposed carbonate configurations were examined by solution and solid-phase techniques, including NMR spectroscopic and X-ray crystallographic analyses. Control experiments combined with DFT calculations provide a rationale for the distinct catalytic manifolds observed in the presence and absence of the Al(III) complex.

Published
2020
Full Text
View/download PDF

212. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer.

Author

Dwyer, Andrea J., Murphy, Caitlin C., Boland, C. Richard, Garcia, Reese, Hampel, Heather, Limburg, Paul, Lowery, Jan, Zauber, Ann G., Waring, Stephen, Worrall, Sharyn, Perea, Jose, Siegel, Rebecca, Lee, Jeffrey, Molmenti, Christine, Sears, Cynthia L., Buckhaults, Phillip, Hayes, Richard, Hussan, Hisham, de Miranda, Noel, and Palles, Claire

Published
2019
Full Text
View/download PDF

213. Staging of oropharyngeal squamous cell carcinoma of the head and neck: Prognostic features and power of the 8th edition of the UICC staging manual.

Author

Beltz, Anna, Gösswein, Dorothée, Zimmer, Stefanie, Limburg, Ivonne, Wünsch, Desirée, Gribko, Alena, Deichelbohrer, Maximilian, Hagemann, Jan, Stauber, Roland H., and Künzel, Julian

Subjects
SQUAMOUS cell carcinoma, EDITIONS, NECK, LYMPH nodes
Abstract

Recognizing the prognostic power differentiating HPV-associated oropharyngeal squamous cell cancer (OPSCC) from OPSCC with other causes, the UICC Cancer Staging Manual 8th edition realizes significant changes from the 7th edition. Purpose of this study was to evaluate the differences of prognostic impact between the 7th and the latest edition of TNM Classification as well as to examine risk factors like extranodal extension (ENE) and lymph node ratio (LNR) for HPV-mediated OPSCC. The study includes 255 patients with OPSCC and initial diagnosis between 2008 and 2015. HPV status was determined according to p16 immunohistochemistry (IHC) and all patients were classified as defined by 7th and 8th edition of UICC. Prognostic influence of ENE and LNR was analyzed for patients with HPV-mediated OPSCC. 41.2% of the OPSCC were p16-positive. Implementation of the 8th edition of the UICC lead to a better differentiation between the respective stages. Regarding HPV-positive OPSCC, Kaplan-Meier survival curves showed a significantly better overall survival (OS) for patients with a LNR ≤10% as well as for patients with negative ENE status (p = 0.004, p = 0.008). 8th edition of UICC achieves to differentiate properly between the UICC stages. However, the staging rule of ignoring ENE in HPV-mediated OPSCC should be further analyzed. Moreover LNR might be a possible additional prognostic factor – especially regarding HPV-positive tumors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

214. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands

Author

van Zanten, A, Arends, S, Roozendaal, C, Limburg, P C, Maas, F, Trouw, L A, Toes, R E M, Huizinga, T W J, Bootsma, H, Brouwer, E, van Zanten, A, Arends, S, Roozendaal, C, Limburg, P C, Maas, F, Trouw, L A, Toes, R E M, Huizinga, T W J, Bootsma, H, and Brouwer, E

Abstract

Objectives To determine the prevalence of anticitrullinated protein antibodies (ACPAs) and their association with known rheumatoid arthritis (RA) risk factors in the general population.Methods Lifelines is a multidisciplinary prospective population-based cohort study in the Netherlands. Cross-sectional data from 40 136 participants were used. The detection of ACPA was performed by measuring anti-CCP2 on the Phadia-250 analyser with levels >= 6.2 U/mL considered positive. An extensive questionnaire was taken on demographic and clinical information, including smoking, periodontal health and early symptoms of musculoskeletal disorders. RA was defined by a combination of self-reported RA, medication use for the indication of rheumatism and visiting a medical specialist within the last year.Results Of the total 40 136 unselected individuals, 401 (1.0%) had ACPA level >= 6.2 U/mL. ACPA positivity was significantly associated with older age, female gender, smoking, joint complaints, RA and first degree relatives with rheumatism. Of the ACPA-positive participants, 22.4% had RA (15.2% had defined RA according to our criteria and 7.2% self-reported RA only). In participants without RA, 311 (0.8%) were ACPA-positive. In the non-RA group, older age, smoking and joint complaints remained significantly more frequently present in ACPA-positive compared with ACPA-negative participants.Conclusions In this large population-based study, the prevalence of ACPA levels >= 6.2 U/mL was 1.0% for the total group and 0.8% when excluding patients with RA. Older age, smoking and joint complaints were more frequently present in ACPA-positive Lifelines participants. To our knowledge, this study is the largest study to date on ACPA positivity in the general, mostly Caucasian population.

Published
2017

215. Member Adherence to a Health Insurer-Sponsored Gap Closure Program Using Multi-Target Stool DNA Test for Colorectal Cancer Screening

Author

Greene, Mallik, Pew, Timo, Le, Quang, Philp, Alisdair, Johnson, William K., Ozbay, A. Burak, Kisiel, John, Dore, Michael, Ebner, Derek, Fendrick, A. Mark, and Limburg, Paul

Abstract

Objectives: To describe member adherence to a mail-based, health insurer-sponsored gap closure program for colorectal cancer (CRC) screening using multi-target stool DNA (mt-sDNA; Cologuard®) tests.Methods: Combined patient data from Exact Sciences Laboratories LLC and data from mass-mailed mt-sDNA orders placed by a large Medicare Advantage Insurance Plan were analyzed (03/01/2023-06/30/2023). Adherence and time to test return were the primary and secondary outcomes, respectively. Their association with patient characteristics was evaluated using multivariable regression.Results: Among the 3201 member-patients included (86.6% aged 65-75 years; 58.7% female), adherence rate was 49.4%, and mean time to test return was 25.5 days. After multivariable adjustment, the odds of test return were significantly higher among 65- to 75-year-olds (odds ratio [OR] = 1.59 relative to 45- to 64-year-olds), those living in small towns (OR = 1.43 relative to metropolitan-located individuals), and with digital outreach via both SMS and email (OR = 4.31 relative to no digital outreach). Time to test return was shorter in 65- to 75-year-olds than in 45- to 64-year-olds and was not associated with other patient characteristics.Conclusions: Mass-mailed mt-sDNA tests for CRC screening were associated with an overall adherence rate of about 50% in this Medicare Advantage population, with higher likelihood of test return among patients receiving digital outreach.

Published
2024
Full Text
View/download PDF

216. Insulin-Like Growth Factor (IGF)-1, IGF-Binding Protein-3, and Pancreatic Cancer in Male Smokers

Author

Stolzenberg-Solomon, R. Z., Limburg, P., Michael Pollak, Taylor, P. R., Virtamo, J., and Albanes, D.

Subjects
Male, Pancreatic Neoplasms, Insulin-Like Growth Factor Binding Protein 3, Oncology, Risk Factors, Epidemiology, Case-Control Studies, Odds Ratio, Humans, Insulin-Like Growth Factor I, Middle Aged, Aged
Abstract

To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50–69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37–1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38–1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50–1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.

Published
2004
Full Text
View/download PDF

219. National survey of blindness and visual impairment in Guatemala, 2015.

Author

Serrano Chávez, Gloria Marina, Salazar de Barrios, Ana Rafaela, Figueroa Pojoy, Oscar Leonel, del Rosario Monzón Herrera de Reyes, Aida, Yee Melgar, Mariano, Yee Melgar, Juan Francisco, de León Régil, Mario, Mendoza Hernandez, Carlos Alberto, Miranda Chanquin, Victor Alfonso, Diaz, Evelyn, Lansingh, Van C., Limburg, Hans, Silva, Juan Carlos, and Furtado, João M.

Abstract

Copyright of Arquivos Brasileiros de Oftalmologia is the property of Arquivos Brasileiros de Oftalmologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

220. HMGB1 in ANCA-associated vasculitis: A longitudinal study

Author

Souza, A.W.S., Westra, J., Bijzet, J., Limburg, P., Bijl, M., Kallenberg, C.G.M., Translational Immunology Groningen (TRIGR), and Groningen Institute for Organ Transplantation (GIOT)

Subjects
creatinine blood level, diagnosis, rheumatology, chemical and pharmacologic phenomena, histone, vasculitis, remission, gender, follow up, biopsy, human, rheumatic disease, ANCA associated vasculitis, relapse, therapy, C reactive protein, microscopic polyangiitis, granulomatosis, longitudinal study, DNA, Churg Strauss syndrome, DNA binding protein, enzyme linked immunosorbent assay, female, disease exacerbation, patient, proteinuria, disease activity, serum, glomerulonephritis
Abstract

Background High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunologic competent cells. Higher levels of HMGB1 have been found in ANCA-associated vasculitis (AAV), especially in patients with granulomatosis with polyangiitis (GPA) and active disease. HMGB1 has been associated with granulomatous manifestations of GPA and with biopsy-proven renal involvement in AAV. Objectives To measure HMGB1 levels longitudinally in a cohort of patients with AAV in order to evaluate the association with disease activity, remission, relapses, and specific organ involvement. Methods HMGB1 levels were tested by ELISA at diagnosis, at least twice during the remission period and during a disease flare. Disease activity was ascertained using the Birmingham Vasculitis Activity Score (BVAS). Results 50 patients with AAV and 35 age and sex matched healthy controls (HC) (58.5±14.1 years vs. 55.1±11.7 years at baseline; P=0.256), frequency of females (44.0% vs. 51.4%; P =0.499) were included. The frequency of each AAV subgroup was as follows: GPA (62%), microscopic polyangiitis (MPA) (20%), isolated necrotizing glomerulonephritis (iNGN) (16%) and Churg-Strauss syndrome (CSS) (2%). Localized disease was found in 16% and renal involvement in 74% at disease onset. Patients and HC had similar mean levels of HMGB1 at baseline (2.61±1.83 vs. 2.34±0.94 ng/mL; P=0.389). Patients with localized disease presented higher median levels of HMGB1 than those with generalized disease but this difference was not significant [3.14 (0.50-9.03) vs. 1.97 (0.46-7.54) ng/mL; P=0.233] whereas patients with renal involvement had lower levels of HMGB1 in comparison to those without renal involvement at baseline (2.29±1.48 vs. 3.52±2.41 ng/mL; P=0.035). Negative correlations were found between serum HMGB1 and 24 hours proteinuria levels (ρ = -0.352; P=0.038) and between HMGB1 and serum creatinine at baseline (ρ = -0.287; P=0.045). The mean follow-up period was 53.4 months and at least one relapse was observed in 34.0% of patients. Among relapsing patients, at least one relapse was found in 64.7% and 2 relapses in 35.3%. At baseline, relapsing patients presented significantly higher mean BVAS when compared to non-relapsing patients (20.2±8.8 vs. 15.3±5.8; P=0.038) while other baseline features were similar between relapsing and non-relapsing patients including age, gender, ANCA specificity, HMGB1 and C-reactive protein (CRP) levels. Median HMGB1 levels were as follows: 2.12 ng/mL at baseline, 1.44 ng/mL and 1.90 ng/mL in patients in remission 3 and 11 months after commencing therapy (P=0.029). Median HMGB1 levels were 2.26 ng/mL and 2.04 ng/mL in the first and in the second relapse, respectively. Conclusions Serum HMGB1 levels were similar between patients with AAV and controls at baseline and renal involvement may account for unexpectedly lower levels of HMGB1 in patients with AAV at baseline, possibly due to urinary loss in patients with proteinuria. No clear relation between HMGB1 levels and disease activity could be found. Nonetheless, a significant decrease in HMGB1 levels was observed in AAV patients from baseline to remission.

Published
2013

221. Eular workshop on Rheumatology Research: Noordwijkerhout February 1982

Author

Bjelle, A., Cedergren, B., Wählby, L., Boerbooms, A. P. Th., Geerdink, P. J., van de Putte, L. B. A., Ouweland, F. A. M., Buchanan, R. R. C., Morgan, A., Staines, N. A., Venables, P. J. W., Maini, R. N., Bucknall, R. C., Bacon, P. A., Jones, J. Verrier, Leirisalo, M., Laitinen, O., Bühring, M., Rosak, C., Stöckle, W., Magnet, W., Catogio, L. J., Bernstein, R. M., Black, C. M., Hughes, G. R. V., Maddison, P. J., Charles P. J., Venables P. J. W., Tung Yi., Buchanan R. C., Maini R. N., Deicher, H., Weißbarth, E., Zeller, J., Baruth, B., Delbarre, F., de Gery, A., Kahan, A., de Vries, E., van der Veen, C. J. P., van der Weij, J. P., Klein, F., de Bruijn, A. M., Cats, A., Dreher, R., Coworkers, Duclos, M., Peter, H., Zeidler, H., Rieber, P., Pichler, J., Limany, W., Dunn, N., Hurst, N. P., Denholm, E., Nuki, G., Ebringer, A., Hayes, J., Cowling, P., Ebringer, R., Egeland, T., Forre, Ø., Festen, J. J. M., Kuipers, F. H., Schaars, A. H., Førre, Ø., Waalen, K., Mellbye, O. J., Froebel, K., Lewis, D., Sturrock, R. D., Goldschmeding, R., Limburg, P. C., Pastoor, G. W., Houtman, P. M., Kallenberg, C. G. M., Halberg, P., Lorenzen, I., Bennedsen, J., Rhodes, J. M., Hall, N. D., Eales, L. -J., Blake, D. R., Hunneyball, I. M., Helmke, K., Boeder, T., Teuber, J., Hermanns, P., Veys, E. M., Verbruggen, G., Horsfall, A. C., Mumford, P. A., Schrieber, L., Huber, O., Kluin-Nelemans, H., Vernooy, J., Meyling, F. Gmelig, Derksen, R., Kater, L., Hurst N. P., Nuki G., Husby, G., Gran, J. T., Thorsby, E., Johnson, G. D., Bainbridge, D. R., Holborow, E. J., Bubel, M., Goddard, D. H., Jonsson, J., Norberg, R., Schilling, W., Kalden, R., Leitner, O., Manger, B., Beck, A., Koch, B., de Jong, M. C. J. M., Walstra, T., van der Meulen, J., Kávai, M., Bányai, A., Zsindely, A., Sonkoly, I., Szegedi, Gy., Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D., Wigzell, H., Koivuranta, P., Repo, H., Kiistala, U., Österman, P., Konttinen, Y., Friman, C., Tolvanen, E., Johansson, E., Konttinen, Y. T., Reitamo, S., Seppä, A., Malmström, M., Lindström, F., Hellquist, H., Olofsson, J., Maddison, PJ., Black, CM., Jayson, MIV, Batchelor, J. R., Walsh, Kl., Bernstein, RM, Catoggio, LJ., Holland, CD., Hughes, GRV, Mbuyi, J. M., Dequeker, J., Förre Ö, Johnsen, W., Meijer, C. J. L. M., de Graaf-Reitsma, C., Lafeber, G. J. M., Meyer, O., Borda-Oriarte, O., Haïm, T., Ryckewaert, A., Mielants, H., Van Steenkiste, M., De Langhe, J., Buchanan, R. C., Moutsopoulos, M., Hooks, J., Mumford, P., Patel, V., Panayi, G. S., Piatier-Tonneau, D., Mach, P. S., Plater-Zyberk, C., Clarke, M., Raeman, F., De Cock, W., Leempoels, J., De Cree, J., Verhaegen, H., Ranki, A., Paavonen, T., Kankaanpää, U., Nilsson, E., Biberfeld, G., Room, G., Saal, J. G., Frank, F., Rauteenstrauch, H., Hadam, M., Fritz, P., Laschner, W., Scheper, R. J., von Blomberg-van der Flier, B. M. E., Boerrigter, G. H., van Bruynzeel, D., van Dinther-Janssen, A. C. H. M., Simon, K. H., Schmidt, R. E., Erhardt, C. C., Melsom, R. D., McCarthy, J., Smeenk, R., Van der Lelij, G., Aarden, L., Staite, N. D., Stierle, H. E., Brown, K. A., Perry, J. D., Swaak, A. J. G., Groenwold, J., Smeenk, R. J. T., Toenes, G. H., Edel, H. H., Eggert, K., Held, E., Hübner, F. K., Schattenkirchner, M., Wegelius, O., Tron, F., Jacob, L., Bach, J. F., Lens, J. W., van den Berg, W. B., van Rijswijk, M. H., van Leeuwen, M. A., van der Giessen, M., The, T. H., van Venrooij, W. J., van Eekelen, C. A. G., Habets, W. J. A., Salden, M. H. L., de Rooij, D. J., Van Wanghe, P., Hermanns, Ph., Van Bruwaene, Ph., De Brabanter, G., De Landsheere, D., Immesoete, C., Walravens, M. J. F., Stevens, E., Warnatz, H., Lemm, G., Wiik, A., Petersen, J., Permin, H., Wollheim, F. A., Carlsson, J., Forsgren, A., Pettersson, H., Youinou, P., Miossec, P., and Le Goff, P.

Published
1982
Full Text
View/download PDF

222. IX Eular Workshop for Rheumatology Research: Molecular biology of autoantigens, autoantibodies and immunopeptides. Vienna, Austria, March 9–12, 1989

Author

Fournier, C., Texier, B., Chiocchia, G., Boissier, M. C., Herbage, D., Brown, C. M. S., Zyberk, C. Plater, Maini, R. N., Palacios, A., Sieper, J., Heinegard, D., Panayi, G. S., Gentric, A., Mackenzie, L., Lydyard, P. M., Youinou, P., Menzel, E. J., Kaik, B., Sykulev, Yu. K., Guschin, A. Je., Vasiljev, V. I., Ostreiko, K. K., Yeronina, T. V., Tumanova, I. A., Moynier, M., Abderrazik, M., Combe, B., Rucheton, M., Brochier, J., Tuomi, T., Palosuo, T., Heliövaara, M., Aho, K., McHugh, N. J., James, I. E., Kallenberg, C. G. M., Tervaert, J. W. Cohen, Goldschmeding, R., Von Dem Borne, A. E. G. K. R., Bouanani, M., Piechaczyk, M., Pau, B., Bastide, M., Le Page, S., Williams, W., Parkhouse, D., Cambridge, G., Isenberg, D. A., Nimmegeers, J., De Keyser, F., Verbruggen, G., Veys, E. M., Walravens M. J. F., Verdeyen I., Vandepol B., Cortens W., Schatteman, L., Goethals, K., Wu, D. -H., Tavoni, A., Neri, R., Garzelli, C., Vitali, C., Bombardieri, S., Logar, D., Kveder, T., Dobovisek, J., Rozman, B., Menard, H. A., Boire, G., Lopez-Longo, F. J., Masson, Ch., Lapointe, S., Clair, E. W. St., Zerva, L., Moutsopoulos, H. M., Keene, J. D., Pisetsky, D. S., Van Dam, A. P., Cuypers, H. T. M., Winkel, I., Smeenk, R. J. T., Taylor, D., Valente, E., Foster, J. P., Williams, D. G., Stocks, M. R., Caporali, R., De Gennaro, F., Cerino, A., Cobianchi, F., Astaldi-Ricotti, G. C. B., Montecucco, C., Habets, W., Sillekens, P. T. G., Hoet, M. H., McAllister, G., Lerner, M. R., Van Venrooij, W. J., Habets, W. J., Van Der Kemp, A., De Jong, B., Scarpa, R., Pucino, A., Di Girolamo, C., della Valle, G., Larizza, G., Casiere, D., Oriente, P., Paimela, L., Palvimo, J., Kurki, P., Hassfeld, W., Steiner, G., Graninger, W., Smolen, J. S., Lopez-Longo, E. J., Larose, A., Hoet, R., Zewald, R., Smeenk, R., Brinkman, K., Van Den Brink, H., Westgeest, A., Huss, R., Krapf, E. F., Herrmann, M., Leitmann, W., Kalden, J. R., Merétey, K., Cebecauer, L., Böhm, U., Kozakova, D., Brózik, M., Temesvári, P., Nagy, L., Bozic, B., Stegnar, M., Vene, N., Peternel, P., Giuggioli, C., Monti, P., Rossi, G., Ferri, C., Chiellini, S., Baboonian, C., Venables, P. J. W., Roffe, L., Booth, J., Krapf, F., Abuljadayel, I., Ebringer, A., Cox, N. L., Brand, S. R., McIntosh, D. P., Bernstein, R. M., Van Den Broek, M. F., Van Bruggen, M. C. J., Smetsers, T., Kuyer, P., Van De Putte, L., Van Den Berg, W. B., Toivanen, A., Jalkanen, S., Lahesmaa-Rantala, R., Isomäki, O., Pekkola-Heino, K., Merilahti-Palo Saario, R., Von Essen, R., Isomäki, H., Granfors, K., Gaston, J. S. H., Life, P. F., Bailey, L., Bacon, P. A., Khalafpour, S., Wilson, C., Awad, J., Toivanen, P., Saario, R., Skurnik, M., Van Der Straeten, C., Mielants, H., Gazic, M., Hartung, K., Riedel, T., Stannat, S., Specker, Ch., Röther, E., Pirner, K., Schendel, D., Baur, M., Corvetta, A., Peter, H. H., Lakomek, H. J., Deicher, H., Andonopoulos, A. P., Papasteriades, C. A., Drosos, A. A., Dimou, G. S., Shattles, W., Venables, P., Charles, P. J., Markwick, J. R., Venables, P. J., Galeazzi, M., Lulli, P., Tuzi, T., Cappellacci, S., Morellini, M., Trabace, S., Cutrupi, F., Sorrentino, R., Botti, S., Iannicola, C., Costanzi, S., Tosi, R., Gospodinoff, A., Eliaou, J. F., Humbert, H., Balaguer, P., Nicolas, J. C., Sany, J., Clot, J., Sakkas, L. I., Bird, H., Welsh, K. I., Pitzalis, C., Kingsley, G., Haskard, D., Vischer, T. L., Bas, S., Werner-Favre, C., Wohlwend, D., Zubler, R. H., Afeltra, A., De Pita, O., Basso, P., Pietrucci, A., Ferri, G. M., Bonomo, L., Gerli, R., Cernetti, C., Bertotto, A., Agea, E., Arcangeli, C., Lanfrancone, L., Rambotti, P., Crupi, S., Baglioni, A., Spinozzi, F., Papazoglou, S., Skoumi, D., Athanasiou, P., Iliopoulos, A., Stavropoulou, A., Kontomerkos, T., Hendrich, G., Kuipers, J. G., Hammer, M., Schmidt, R. E., Manoussakis, M. N., Germandis, G., Zerva, L. V., Siouna-Fatourou, H. J., Katsikis, P. D., Mavridis, A., Toubert, A., Sadouk, M., de la Tour, B., Vaquero, C., Amor, B., Miossec, P., Naviliat, M., Cretien, I., Banchereau, J., Graninger, P., Aschauer, B., Sinski, A., Smolen, J., Krutmann, J., Kirnbauer, R., Köck, A., Schwarz, T., May, L. T., Sehgal, P. B., Luger, T. A., Field, M., Chu, C. Q., Feldmann, M., Wilbrink, B., Nietfeld, J. J., Helle, M., Boeije, L. C. M., Van Roy, J. L. A. M., Den Otter, W., Aarden, L. A., Huber-Bruning, O., Malejczyk, J., Urbanski, A., Malejczyk, M., Karbowski, A., Völker, W., Feige, U., Otter, W. Den, Malfait, A. M., Wieme, N., Gyselbrecht, L., Van de Loo, A. A. J., Van Lent, P. L. E. M., Haskard, D. O., Wellicome, S., Lanchbury, J., Thornhill, M., Krutmann, K., Gschnait, F., Yaron, M., Yaron, I., Dayer, J. -M., Bleiberg, I., Meyer, F. -A., Maury, C. P. J., Teppo, A. -M., Salo, E., Pelkonen, P., Malfait, A., Cochez, Ph., Gruschwitz, M., Müller, P. U., Wick, G., Madhok, R., Wilson, R., Frame, M., Thompson, J., Sturrock, R. D., Partsch, G., Matucci-Cerinic, M., Marabini, S., Jantsch, S., Neumüller, J., Eberl, R., van Beuningen, H. M., Arntz, O. J., Zlabinger, G. J., Steffen, C., Brand, H. S., Van Kampen, G. P. J., De Koning, M. H. M. T., Kiljan, E., Van Der Korst, J. K., Gemmell, C. G., Swaak, A. J. G., Van Rooyen, A., Hall, N. D., Woolf, A. D., Kantharia, B., Maymo, J., Blake, D. R., Goulding, N. J., Maddison, P. J., Munthe, E., Berntzen, H. B., Fagerhol, M., Mathieu, A., Pala, R., Contu, L., Cirillo, R., Garau, P., Nurchis, P., Viberti, G. C., Meyer, O., Zenklusen, C., Le Thi Huong Du, Z., Gaudouen, C., Mery, J. Ph., Ronco, P., Kahn, M. F., Rasmussen, N., Szpirt, W., Thomsen, B., Humbel, R. L., Ter Borg, E. J., Horst, G., Hummel, E., Limburg, P. C., Aeschilmann, A., Bourgeois, P., De Rooij, D. J., Van de Putte, L. B. A., Verbeek, L., Farinaro, C., Infranzi, E., Couret, M., Ackerman, C., De Vlam, K., Carapic, V., Carapic, D., Annefeld, M., Erne, B., Rosenwasser, L. J., Pazoles, C. J., Otterness, I. G., Hanson, D. C., McDonald, B., Loose, L. D., Dougados, M., Machold, K. P., Wiesenberg-Böttcher, I., Wanner, K., Pignat, W., Altmann, H., Tuschl, H., Bröll, H., Balestrieri, G., Tincani, A., Cattaneo, R., Bertoli, M. T., Martinelli, M., Allegro, F., Meroni, P. L., Balesini, G., Aichinger, G., Schlögl, E., Huber, Ch., Shoenfeld, Y., Fleishmaker, E., Mendlovic, S., Mozes, E., Blank, M., Talal, N., Hogervorst, E. J. M., Van Eden, W., Van Der Zee, R., Psychos, D., Dimou, G., Stefanaki-Nikou, S., Papadimitriou, C. S., Settas, L., Alexiou, P., Dimitriadis, G., Mataftsi, E., Soliou, E., Tourkantonis, A., Babic, M., Jeurissen, M. E. C., and Boerbooms, A. MTh

Published
1989
Full Text
View/download PDF

224. Bias-Driven Conductance Increase with Length in Porphyrin Tapes.

Author

Leary, Edmund, Limburg, Bart, Alanazy, Asma, Sangtarash, Sara, Grace, Iain, Swada, Katsutoshi, Esdaile, Louisa J., Noori, Mohammed, González, M. Teresa, Rubio-Bollinger, Gabino, Sadeghi, Hatef, Hodgson, Andrew, Agraı̈t, Nicolás, Higgins, Simon J., Lambert, Colin J., Anderson, Harry L., and Nichols, Richard J.

Published
2018
Full Text
View/download PDF

225. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)‑2,2-Difluoro-cyclo-propyl)-((1R,5S)‑3-(2-((1-methyl‑1H‑pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diaza-bicyclo-[3.2...

Author

Fensome, Andrew, Ambler, Catherine M., Arnold, Eric, Banker, Mary Ellen, Brown, Matthew F., Chrencik, Jill, Clark, James D., Dowty, Martin E., Efremov, Ivan V., Flick, Andrew, Gerstenberger, Brian S., Gopalsamy, Ariamala, Hayward, Matthew M., Hegen, Martin, Hollingshead, Brett D., Jussif, Jason, Knafels, John D., Limburg, David C., Lin, David, and Lin, Tsung H.

Published
2018
Full Text
View/download PDF

226. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).

Author

Phipps, Amanda I., Qian Shi, Zemla, Tyler J., Dotan, Efrat, Gill, Sharlene, Goldberg, Richard M., Hardikar, Sheetal, Jahagirdar, Balkrishna, Limburg, Paul J., Newcomb, Polly A., Shields, Anthony, Sinicrope, Frank A., Sargent, Daniel J., and Alberts, Steven R.

Abstract

Background: Prior studies have supported an inverse association between physical activity and colon cancer risk and suggest that higher physical activity may also improve cancer survival. Among participants in a phase III adjuvant trial for stage III colon cancer, we assessed the association of physical activity around the time of cancer diagnosis with subsequent outcomes. Methods: Before treatment arm randomization (FOLFOX or FOLFOX + cetuximab), study participants completed a questionnaire including items regarding usual daily activity level and frequency of participation in recreational physical activity (N = 1,992). Using multivariable Cox models, we calculated HRs for associations of aspects of physical activity with disease-free (DFS) and overall survival (OS). Results: Over follow-up, 505 participants died and 541 experienced a recurrence. Overall, 75% of participants reported recreational physical activity at least several times a month; for participants who reported physical activity at least that often (vs. once a month or less), the HRs for DFS and OS were 0.82 [95% confidence interval (CI), 0.69-0.99] and 0.76 (95% CI, 0.63-0.93), respectively. There was no evidence of material effect modification in these associations by patient or tumor attributes, except that physical activity was more strongly inversely associated with OS in patients with stage T3 versus T4 tumors (Pinteraction = 0.03). Conclusions: These findings suggest that higher physical activity around the time of colon cancer diagnosis may be associated with more favorable colon cancer outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

227. Lifetime Chronicles of Selenium Exposure Linked to Deformities in an Imperiled Migratory Fish

Author

Johnson, Rachel Cathleen, Stewart, A. Robin, Limburg, Karin E., Huang, Rong, Cocherell, Dennis, and Feyrer, Frederick

Abstract

Aquatic ecosystems worldwide face growing threats from elevated levels of contaminants from human activities. Toxic levels of selenium (Se) shown to cause deformities in birds, fish, and mammals can transfer from parents to progeny during embryonic development or accumulate through Se-enriched diets. For migratory species that move across landscapes, tracking exposure to elevated Se is vital to mitigating vulnerabilities. Yet, traditional toxicological investigations resolve only recent Se exposure. Here, we use a novel combination of X-ray fluorescence microscopy and depositional chronology in a biomineral to reveal for the first time provenance, life stage, and duration of toxic Se exposure over the lifetime of an organism. Spinal deformities observed in wild Sacramento Splittail (Pogonichthys macrolepidotus), an imperiled migratory minnow, were attributed to elevated Se acquired through maternal transfer and juvenile feeding on contaminated prey. This novel approach paves the way for diagnosing sources, pathways, and potential for a cumulative exposure of Se relevant for conservation.

Published
2020
Full Text
View/download PDF

230. Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections

Author

Naidoo, Kovin, Kempen, John H, Gichuhi, Stephen, Braithwaite, Tasanee, Casson, Robert J, Cicinelli, Maria Vittoria, Das, Aditi, Flaxman, Seth R, Jonas, Jost B, Keeffe, Jill Elizabeth, Leasher, Janet, Limburg, Hans, Pesudovs, Konrad, Resnikoff, Serge, Silvester, Alexander J, Tahhan, Nina, Taylor, Hugh R, Wong, Tien Y, and Bourne, Rupert R A

Abstract

BackgroundThis study aimed to assess the prevalence and causes of vision loss in sub-Saharan Africa (SSA) in 2015, compared with prior years, and to estimate expected values for 2020.MethodsA systematic review and meta-analysis assessed the prevalence of blindness (presenting distance visual acuity <3/60 in the better eye), moderate and severe vision impairment (MSVI; presenting distance visual acuity <6/18 but ≥3/60) and mild vision impairment (MVI; presenting distance visual acuity <6/12 and ≥6/18), and also near vision impairment (

Published
2020
Full Text
View/download PDF

231. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Author

Michels, Sebastian, Massutí, Bartomeu, Schildhaus, Hans-Ulrich, Franklin, Jeremy, Sebastian, Martin, Felip, Enriqueta, Grohé, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S.Y., Bischoff, Helge, Brandts, Christian, Carcereny, Enric, Corral, Jesús, Dingemans, Anne-Marie C., Pereira, Eva, Fassunke, Jana, Fischer, Rieke N., Gardizi, Masyar, Heukamp, Lukas, Insa, Amelia, Kron, Anna, Menon, Roopika, Persigehl, Thorsten, Reck, Martin, Riedel, Richard, Rothschild, Sacha I., Scheel, Andreas H., Scheffler, Matthias, Schmalz, Petra, Smit, Egbert F., Limburg, Meike, Provencio, Mariano, Karachaliou, Niki, Merkelbach-Bruse, Sabine, Hellmich, Martin, Nogova, Lucia, Büttner, Reinhard, Rosell, Rafael, and Wolf, Jürgen

Abstract

ROS1rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS).

Published
2019
Full Text
View/download PDF

240. Eighth annual meeting of the European Association for the Study of Diabetes: Madrid, Spain September, 6–8, 1972

Author

Alberti, K. G. M. M., Darley, J., Emerson, Pauline M., Hockaday, T. D. R., Amherdt, M., Like, A. A., Blondel, B., Marliss, B., Wollheim, C., Orci, L., Andersen, O. Ortved, Andersson, Arne, Antonini, F. M., Fumagalli, C., Petruzzi, E., Bertini, G., Mori, S., Tinti, P., Ashcroft, S. J. H., Weerasinghe, L. C. C., Randle, P. J., Assan, R., Slusher, N., Guy-Grand, B., Girard, F., Soufflet, E., Attali, J. R., Ballerio, G., Boillot, J., Atkins, T., Matty, A. J., Bailey, C. J., Aynsley-Green, A., Bloom, S. R., Bacchus, R. A., Meade, L. G., London, D. R., Balant, L., Zahnd, G., Petitpierre, B., Fabre, J., Balasse, E. O., Neef, M. A., Barta, L., Brooser, G., Molnar, Maria, Bataille, D. P., Freychet, P., Kitabgi, P., Rosselin, G. E., Berne, Christian, Beyer, J., Cordes, U., Sell, G., Rosak, C., Schöffling, K., Birkner, B., Henner, J., Wagner, P., Erhardt, F., Dieterle, P., Bloom, S. R., Vaughan, N. J. A., Edwards, A. V., Boquist, L., Brand, I., Söling, H. D., Brandenburg, D., Gliemann, J., Ooms, H. A., Puls, W., Wollmer, A., Camerini-Davalos, R. A., Bloodworth, Jr., J. M. B., Limburg, B., Oppermann, W., Campbell, A. K., Siddle, K., Cañadell, J. M., Barraquer, J., Muiños, A., Heredia, C. D., Castillo-Olivares, J., Guijo, J., Pallardo, L. F., Cerasi, E., Efendić, S., Luft, R., Cerasi, E., Wahren, J., Luft, R., Felig, P., Christensen, Niels Juel, Christiansen, A. H., Vølund, A., Connon, J. J., Trimble, E., Copinschi, G., Leclercq, R., Bruno, O. D., Cordes, U., Sell, G., Beyer, J., Haupt, E., Schöffling, K., Creutzfeldt, C., Track, N. S., Cuendet, G. S., Wollheim, C. B., Cameron, D. P., Balant, L., Stauffacher, W., Marliss, E. B., Czyzyk, A., Lao, B., Bartosiewicz, W., Szczepanik, Z., De Nobel, E., Laar, A. Van't, Koene, R. A. P., Benraad, Th. J., Dietze, G., Hepp, K. D., Wickmayr, M., Mehnert, H., Dixon, K., Exon, P. D., Hughes, H. R., Jones, D. W., Elkeles, R. S., Exon, P. D., Dixon, K., FitzGerald, M. G., Malins, J. M., Falorni, A., Massi-Benedetti, F., Gallo, G., Maffei, S., Fedele, D., Tiengo, A., Muggeo, M., Fabris, P., Crepaldi, G., Federlin, K., Helmke, K., Slijepčević, M., Pfeiffer, E. F., Felber, J. P., Oulès, J., Schindler, Ch., Chabot, V., Fernandez-Cruz, Jr., A., Catalán, E., Otero, M. Luque, Hermida, O. Garcia, Otero, M. Luque, Catalán, E., Flatt, J. P., Blackburn, G., Randers, G., Förster, H., Hoos, I, Lerche, D., Förster, H., Hoos, I., Matthäus, M., Franckson, J. R. M., Ooms, H. A., Frerichs, H., Daweke, H., Gries, F., Grüneklee, D., Hessing, J., Jahnke, K., Keup, U., Miss, H., Otto, H., Puls, W., Schmidt, D., Zumfelde, C., Funcke, H. v., Löffler, G., Wieland, O., Galton, D. J., Guttman, R., Gazzola, G. C., Franchi, R., Ronchi, P., Saibene, V., Guidotti, G. G., Gligore, V., Hîncu, N., Tecuceanu, Rodica, Goberna, R., Garcia-Albertos, F., Tamarit-Rodriguez, J., del Rio, E., Roca, R., Gomez-Acebo, José, Creco, A. V., Fedeli, G., Ghirlanda, G., Fenici, R., Lucente, M., Gutman, A., Agam, G., Nahas, N., Cazalis, P., Gylfe, E., Hellman, B., Hadden, D. R., Connolly, J. H., Montgomery, D. A. D., Weaver, J. A., Hellerström, Claes, Howell, Simon, Andersson, Arne, Edwards, John, Sehlin, J., Täljedal, I. -B., Heptner, W., Neubauer, H. B., Herchuelz, A., Pipeleers, D. G., Malaisse, W. J., Herrera, E., Montoya, Eladio, Hommel, H., Fischer, IT., Schmid, B., Fiedler, H., Bibergeil, H., Iversen, J., Iynedjian, P. B., Peters, G., Jacquemin, C., Lambert, B., Sutter, B. Ch. J., Jakob, A., Zapf, J., Froesch, E. R., Jansen, F. K., Freytag, G., Herberg, L., Jarrett, R. J., Baker, I. A., Jarrousse, C., Rancon, F., Rosselin, G. E., Job, D., Tchobroutsky, G., Eschwege, E., Guyot-Argenton, C., Aubry, J. P., Déret, M., Karman, H., Mialhe, P., Kissebah, A., Tulloch, B., Fraser, Russell, Kissebah, A., Tulloch, B., Vydelingum, N., Fraser, Russell, Kissing, J., Raptis, S., Dollinger, H., Faulhaber, J., Rothenbuchner, G., Pfeiffer, E. F., Kleineke, J., Sauer, H., Söling, H. D., Kloeze, J., Kohner, Eva M., Sutcliffe, Barbara A., Tudball, M., Dollery, C. T., Korp, W., Neubert, J., Bruneder, H., Lenhardt, A., Levett, R. E., Koschinsky, T., Gries, F. A., Landgraf-Leurs, M. M. C., Landgraf, R., Hörl, R., Langslow, D. R., Laube, H., Fussgänger, R., Mayer, R., Pfeiffer, E. F., Laube, H., Fussgänger, R., Klör, H., Pfeiffer, E. F., Lázaro, E., Leclercq-Meyer, V., Marchand, J. J., Malaisse, W., Ledet, Thomas, Lefébvre, P. J., Luyckx, A. S., Le Marchand, Y., Assimacopoulos, F., Singh, A., Amherdt, M., Rouiller, Ch., Jeanrenaud, B., Lenti, G., Frezzotti, R., Angotzi, G., Bardelli, A. M., Pagano, G., Basetti-Sani, A., Galli, M., Lernmark, Å., Fex, G., Lindsay, D. G., Loge, O., Lopez-Quijada, C., Chiva, L., Rodriguez-Lopez, M., Loten, E. G., Loubatières, A. L., Loubatières-Mariani, M. M., Ribes, G., Chapal, J., Lubetzki, J., Duprey, J., Sambourg, Cl., Lefebvre, P. J., Maier, V., Hinz, M., Schatz, H., Nierle, C., Pfeiffer, E. F., Malaisse, W. J., Pipeleers, D. G., Malaisse-Lagae, F., Orci, L., Malaisse-Lagae, F., Amherdt, M., Ravazzola, M., Stauffacher, W., Orci, L., Renold, A. E., Manzano, P., Rojas-Hidalgo, E., Marco, J., Diaz-Fierros, D., Calle, C., Roman, D., Villanueva, M. L., Valverde, I., Marliss, E. B., Wollheim, C. B., Blondel, B., Orci, L., Like, A., Amherdt, M., Stauffacher, W., Massi-Benedetti, F., Luycks, A. L., Fracassini, F., Lefebvre, P. J., Falorni, A., Menzel, R., Michaelis, D., Neumann, I., Bibergeil, H., Schulz, B., Wilke, W., Wulfert, P., Krämer, K., Menzinger, G., Fallucca, F., Tamburrano, F., Carratu', R., Andreani, D., Metzger, P., Franken, P., Balasse, E. O., Michael, R., Hildmann, W., Jutzi, E., Michl, J., Fankhauser, S., Schlichtkrull, J., Mirouze, J., Orsetti, A., Vierne, Y., Arnoux, N., Mølsted-Pederson, L., Tygstrup, Inge, Villumsen, Åge L., Pedersen, Jørgen, Montague, W., Howell, S. L., Moody, A. J., Agerbak, G. S., Sundby, F., Muggeo, M., Crepaldi, G., Fedele, D., Baritussio, A., Naeser, Peter, Navalesi, R., Pilo, A., Lenzi, S., Cecchetti, P., Corsini, G., Donato, L., Nerup, J., Andersen, O. Ortved, Bendixen, G., Egeberg, J., Poulsen, J. E., Nielsen, J. Høiriis, Hansen, F. Mølgaard, Gliemann, J., Niki, A., Niki, H., Koide, T., Lin, B. J., Nikkels, R. E., Terpstra, J., Gay, A., Oakman, R. H., Lazarus, Norman R., Orci, L., Amherdt, M., Stauffacher, W., Like, A. A., Rouiller, C., Renold, A. E., Malaisse-Lagae, F., Ravazzola, M., Ostman, J., Backman, L., Cerasi, E., Luft, R., Hallberg, D., Ostrowski, K., Panten, U., Christians, J., Parving, H. -H., Rasmussen, S. Munkgaard, Marichal, M., Platilovà, H., Dufek, M., Konopàsek, E., Pozuelo, V., Tamarit, J., Suner, A., Castell, C., Pruett, E. D. R., Maehlum, S., Raptis, S., Grebe, B., Chrissiku, M., Rothenbuchner, G., Müller, R., Hinze, H. J., Pfeiffer, E. F., Reinauer, H., Müller-Ruchholtz, E. R., Rietzler, X., Passa, P., Canivet, J., Schatz, H., Otto, J., Hinz, M., Maier, V., Nierle, C., Behrens, G., Bücher, T., Pfeiffer, E. F., Schlumpf, U., Morell, B., Zingg, A., Schönborn, J., Westphal, P., Panten, U., Bloom, G. D., Idahl, L. -A., Lernmark, A., Söderberg, M., Rios, M. Serrano, Hawkins, F. G., Escobar, F., Mato, J. M., Larrodera, L., de Oya, M., Rodriguez-Miñon, J. L., Shafrir, E., Gutman, A., Sitbon, G., Mialhe, P., Skrabalo, Z., Panajatović, N., Papić, Z., Posinovec, J., Stavljenić, A., Lipovac, V., Aganović, I., Soler, N. G., Bennett, M. A., Söling, H. D., Peters, H., Janson, G., Sönksen, P. H., Srivastava, M. C., Tompkins, C. V., Nabarro, J. D. N., Sørensen, N. Schwartz, Ladefoged, K., Wildenhoff, K. E., Sorge, F., Diehl, H. -J., Hoffmann, H., Schwartzkopff, W., Standl, E., Kolb, H., Standl, A., Mehnert, H., Sutherland, H. W., Stowers, J. M., Whetham, J. C. G., Sutter, B. C. J., Billaudel, B., Sutter, B. Ch. J., Sutter-Dub, M. T., Leclercq, R., Jacquot, R., Täljedal, I. B., Tamarit, J., Tamarit-Rodriguez, J., Goberna, R., Gobema, R., Tamás, Jr., Gy., Baranyi, Éva, Baranyi, A., Radvanyi, A., Tatoń, J., Hinek, A., Wiśniewska, A., Tattersall, R. B., Pyke, D. A., Terpstra, J., Slot, J. Bruins, Sande, P. L. M. v. d., Radder, J. K., Waldeok, K. J. J., Muijden, R. C. P. A. v., Tiengo, A., Assan, R., Frerichs, H., Creutzfeldt, W., Turner, D. S., Baker, R. W., Gent, W. G. L., Shabaan, A., Marks, V., Young, D. A. B., Vague, Ph., Heim, H., Laval, C. Martin, Vegezzi, M., Campo, C.Di, Rahamandridona, G., Garron, D., Heyraud, B., Vague, J., Valverde, I., Villanueva, M. L., Lozano, I., Diaz-Fierros, M., Marco, J., Van Assche, F. A., Gepts, W., Van Obberghen, E., Somers, G., Devis, G., Vaughan, G. D., Malaisse-Lagae, F., Orci, L., Malaisse, W. J., Veleminsky, J., Spirova, E., Waldhäusl, W., Frisch, H., Haydl, H., Weiss, L., Löffler, G., Wieland, O., Willms, B., Deuticke, U., Wollheim, C. B., Marliss, E. B., Blondel, B., Orci, L., Like, A., Renold, A. E., Zrůstová, M., and Roštlapil, J.

Published
1973
Full Text
View/download PDF

246. Antibodies to acetylcholine receptors in myasthenia gravis. In vitro synthesis by peripheral blood lymphocytes before and after thymectomy

Author

Kuks, J B, Limburg, P C, Oosterhuis, H J, and The, T H

Subjects
Adult, Male, Thymoma, medicine.medical_treatment, Lymphocyte, Immunology, In Vitro Techniques, Receptors, Nicotinic, Myasthenia Gravis, medicine, Humans, Immunology and Allergy, Longitudinal Studies, Cells, Cultured, Autoantibodies, Acetylcholine receptor, Autoimmune disease, B-Lymphocytes, business.industry, Pokeweed mitogen, Thymectomy, medicine.disease, Myasthenia gravis, Cross-Sectional Studies, medicine.anatomical_structure, Pokeweed Mitogens, Antibody Formation, Female, business, Acetylcholine, Research Article, medicine.drug
Abstract

SUMMARY Pokeweed antiogen (PWM)-d riven in vitro synthesis of antibodies to the acetylcholine receptor (PSA) was stucture. in non-thymoma patients with myasthenia gravis. In a group of 46 patients, the occurrence: of PSA was related to the presence of the thymus or, in operated patients, the absence of a clinical effect of thymectomy. Sixteen patients were followed before and soon after thymectomy. PSA disappeared in all patients, at least temporarily, between 6 weeks and I year afterwards, independent of the clinical course and eventual clinical effect of the operation. A recurrence was found only in one of the five patients who derived no benefit from the operation. These findings support the hypothesis that the therapeutic effect of thymectomy can be explained by removal of a source of autoreactive lymphocytes. There was no correlation between the changes in serum levels of a-AChR and clinical improvement, suggesting a minor role of circulating peripheral blood lymphocytes (PBL) and the thymus in the total production of a-AChR.

Published
1992
Full Text
View/download PDF

247. Hypoxia inducible factor-1-alpha (HIF-1 alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis

Author

Brouwer, E., Gouw, A. S. H., Posthumus, M. D., van Leeuwen, M. A., Boerboom, Alexander L., Bijzet, Johannes, Limburg, P. C., Kallenberg, C. G. M., Westra, J., Bos, R, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Faculteit Medische Wetenschappen/UMCG, and Groningen Institute for Organ Transplantation (GIOT)

Subjects
rheumatoid arthritis, BIOMARKER, vessels, FIBROBLASTS, SYNOVIAL TISSUE, JOINT, HIF-1 alpha, VASCULAR MORPHOLOGY, HUMAN CANCERS, ACTIVATION, PATHWAY, osteoarthritis, inflammation, MACROPHAGES, GENE-EXPRESSION
Abstract

Objectives Despite the important role of the transcription factor HIF-1 alpha in angiogenesis and inflammation, only a few studies on HIF-1 alpha expression have been performed in RA patients. The aim of the present study was to identify the layer in synovial tissue of RA patients where HIF1 alpha is expressed and to find out whether HIF-1 alpha expression is related to both angiogenesis and inflammation in synovium from. RA patients. Methods A reproducible staining method for HIF-1 alpha was developed. HIF-1 alpha-positive cells were quantified in synovial tissue from patients with RA. As control we used synovial tissue from patients with osteoarthritis (OA). The number of HIF-1 alpha-positive cells was compared with the number of blood vessels present and was correlated with the amount of inflammation. The amount of inflammation was determined by counting inflammatory cells, by estimating the proliferation marker Ki67 in inflamed tissue, and by using a recently published synovitis score which gives an accurate estimate of the amount of inflammation present. Results HIF-1 alpha was expressed weakly in the lining layer and strongly in the sublining layer in RA synovial tissue. In contrast, HIF-1 alpha was only weakly expressed in OA synovial tissue. The number of HIF-1 alpha-positive cells correlated strongly with the number of blood vessels in RA synovial tissue and with inflammatory endothelial cell infiltration (blood vessels), cell proliferation (Ki67) and the synovitis score. Conclusions HIF-1 alpha expression is strongest in the sub-lining layer of RA synovium and is related to both angiogenesis and inflammation in synovium from RA patients. These results thus suggest that HIF-1 alpha could serve as an important new therapeutic target in RA, targeting both angiogenesis and inflammation.

Published
2009

248. Autoantibody standardization in The Netherlands

Author

Damoiseaux, J., Tervaert, J.W., Derksen, R., Hamann, D., Hooijkaas, H., Klasen, I.S., Kallenberg, C.G.M., Limburg, P., and Smeenk, R.

Subjects
Auto-immunity, transplantation and immunotherapy [N4i 4]
Abstract

Item does not contain fulltext Several initiatives have been undertaken, independent of the European Autoantibody Standardization Initiative (EASI), to standardize autoantibodies in The Netherlands. The Dutch EASI team has made an inventory of which initiatives on autoantibody standardization are already available and what future plans for autoantibody standardization exist. This inventory will subsequently be used to define what may be addressed by the Dutch EASI team. The Diagnostic Compass, initiated by the association of Dutch health insurance companies, describes methods and relevance of laboratory tests, including autoantibody tests. Recently, this initiative has been taken over by an independent publisher. There is also a national organization involved in developing guidelines in medicine, including guidelines for autoantibody testing. In addition, there is a national foundation for quality assessment in clinical laboratories (SKML). The quality assessment includes a wide array of autoantibodies. Samples are collected and thoroughly investigated by reference laboratories. Interpretation of results and advice to clinicians are part of the program. Feedback on the results of this proficiency testing is given in reports and during meetings to discuss trends, technical issues, and new developments. The last initiative that we discuss is the foundation Referentie Laboratorium Reuma Serologie (RELARES), which was founded to standardize serology in rheumatic diseases by preparing standard sera. Recently, RELARES has been combined with SKML. A new SKML working group, Standardization Autoimmune Serology, has been initiated to continue the work of RELARES. When comparing the already available Dutch initiatives to the international EASI goals, there appears to be a lack of harmonization in testing algorithms, and this issue is the most important topic to be addressed in the near future.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results